Alkermes (ALKS) Competitors $31.45 +0.47 (+1.52%) Closing price 04:00 PM EasternExtended Trading$30.72 -0.72 (-2.31%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, UTHR, INCY, NBIX, EXAS, IONS, and BMRNShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services United Therapeutics Incyte Neurocrine Biosciences Exact Sciences Ionis Pharmaceuticals BioMarin Pharmaceutical Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Is ABEO or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% Alkermes 23.15%24.86%17.14% Does the media refer more to ABEO or ALKS? In the previous week, Alkermes had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 10 mentions for Alkermes and 6 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 0.74 beat Abeona Therapeutics' score of 0.09 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ABEO or ALKS? Abeona Therapeutics currently has a consensus target price of $19.50, indicating a potential upside of 256.49%. Alkermes has a consensus target price of $42.00, indicating a potential upside of 33.55%. Given Abeona Therapeutics' higher possible upside, equities research analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Which has stronger earnings & valuation, ABEO or ALKS? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M80.14-$63.73M$0.707.81Alkermes$1.51B3.45$367.07M$2.0815.12 Which has more volatility & risk, ABEO or ALKS? Abeona Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Do insiders & institutionals believe in ABEO or ALKS? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.4% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAlkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.19B$3.43B$6.11B$10.62BDividend YieldN/A2.27%5.72%4.85%P/E Ratio15.1223.2429.2227.30Price / Sales3.45270.27491.48184.03Price / Cash11.4145.2825.8230.35Price / Book3.4810.6612.476.65Net Income$367.07M-$52.56M$3.32B$276.14M7 Day Performance-1.53%4.97%1.87%0.01%1 Month Performance13.17%16.48%8.40%3.60%1 Year Performance13.50%14.95%63.49%32.76% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.6466 of 5 stars$31.45+1.5%$42.00+33.5%+9.6%$5.19B$1.51B15.121,800News CoverageUpcoming EarningsABEOAbeona Therapeutics4.3392 of 5 stars$5.50+2.2%$19.50+254.5%-17.5%$282.04M$3.50M7.8690News CoverageMEDPMedpace4.341 of 5 stars$544.41+3.1%$430.60-20.9%+52.8%$15.29B$2.11B40.485,900Positive NewsUpcoming EarningsOMCLOmnicell3.4499 of 5 stars$30.20+1.0%$46.71+54.7%-26.5%$1.39B$1.11B60.403,670Positive NewsAMNAMN Healthcare Services4.3434 of 5 stars$19.77+0.5%$23.08+16.8%-51.8%$757.40M$2.98B-2.542,968Short Interest ↓UTHRUnited Therapeutics4.8 of 5 stars$432.69-0.1%$457.21+5.7%+17.4%$19.52B$2.88B16.891,305Analyst ForecastInsider TradeINCYIncyte4.597 of 5 stars$86.17-1.6%$84.79-1.6%+29.8%$16.83B$4.24B19.582,617Upcoming EarningsAnalyst DowngradeNBIXNeurocrine Biosciences4.6482 of 5 stars$141.33+0.9%$163.72+15.8%+19.8%$14.02B$2.36B41.811,800Trending NewsUpcoming EarningsAnalyst ForecastEXASExact Sciences4.4598 of 5 stars$62.73+2.4%$69.19+10.3%-12.8%$11.88B$2.76B-11.557,000Analyst RevisionIONSIonis Pharmaceuticals3.4277 of 5 stars$73.55+0.6%$78.50+6.7%+85.4%$11.72B$705M-39.971,069BMRNBioMarin Pharmaceutical4.9787 of 5 stars$53.07-0.4%$93.26+75.7%-24.3%$10.19B$2.85B15.753,040 Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exact Sciences Alternatives Ionis Pharmaceuticals Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
